HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the appointment of Maureen T. Cronin, Ph.D., as the Company’s Chief Scientific Officer and Senior Vice President as of November 16, 2018. Dr. Cronin is a veteran biotechnology, translational science and diagnostic executive.Continue reading
Author Archive: AZBio
Two UA Surgery Professors Named to Academy of Master Surgeon Educators™
TUCSON, Ariz. – Two University of Arizona College of Medicine – Tucson surgery professors are among 91 surgeons from seven nations selected to the new American College of Surgeons (ACS) Academy of Master Surgeon Educators.
The new Master Surgeon Educators are UA Department of Surgery Chair Leigh Neumayer, MD, MS, FACS, and Professor James H. McClenathan, MD, FACS .Continue reading
AZBio Members Celgene and Novartis Take Home Prix Galien Gold
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.
The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.
FNIH and C-Path achieve first ever qualification of a clinical safety biomarker by FDA
Major milestone will improve detection of drug-induced acute kidney injury in clinical trialsContinue reading
Arizona-based biotech startup BioLab Sciences announces patent for regenerative tissue therapy, MyOwn SkinTM
BioLab Sciences, an innovator in regenerative medicine technologies, today announced its exclusively licensed technology for MyOwn SkinTM, a painless, non-surgical procedure, which leverages a patient’s own skin to produce full-thickness skin grafts in 5-7 days.Continue reading
HTG Molecular Diagnostics Announces the Institute of Oncology Research Has Adopted the HTG EdgeSeq Technology in its Genomics Facility
HTG’s extraction-free, targeted next-generation sequencing technology adopted to support the IOR’s research and clinical trials in hematological cancers and solid tumorsContinue reading
Hope for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
– Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer –
– Tecentriq and nab-paclitaxel significantly reduced the risk of disease worsening or death in both the intention-to-treat and PD-L1-positive populations –
– Clinically meaningful overall survival improvement in the PD-L1-positive population at this interim analysis –
– Data are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress, featured in the press program and simultaneously published in the New England Journal of Medicine on October 20, 2018 –
‘Leading women’ of biotech share insights
Gathered on the 20th floor of a Phoenix skyscraper on a Monday evening, nearly 40 women – and a few brave men – looked out over the valley and shared their “no boundaries” spirit. They came to connect on the topic of women’s leadership in the biotech industry in Arizona at an Arizona Bioscience Week event, “Leading Women: Biotech and Beyond.”Continue reading